Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Herman Burger

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
British Journal of Cancer|August 19, 2016
Loss of SLCO1B3 drives taxane resistance in prostate cancerEllen S de Morrée, René Böttcher, Robert J van Soest, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2010
Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulationMaja J A de Jonge, Marije Slingerland, Walter J Loos, et al.
Cancer Biology & Therapy|November 19, 2005
Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genesHerman Burger, Michael A den Bakker, Johan M Kros, et al.
Clinical Pharmacology and Therapeutics|August 8, 2006
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinibErin R Gardner, Herman Burger, Ron H van Schaik, et al.
Breast Cancer Research and Treatment|June 8, 2015
Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patientsLisette Binkhorst, Jacqueline S L Kloth, Annelieke S de Wit, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
British Journal of Cancer|August 19, 2016
Loss of SLCO1B3 drives taxane resistance in prostate cancerEllen S de Morrée, René Böttcher, Robert J van Soest, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2010
Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulationMaja J A de Jonge, Marije Slingerland, Walter J Loos, et al.
Cancer Biology & Therapy|November 19, 2005
Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genesHerman Burger, Michael A den Bakker, Johan M Kros, et al.
Clinical Pharmacology and Therapeutics|August 8, 2006
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinibErin R Gardner, Herman Burger, Ron H van Schaik, et al.
Breast Cancer Research and Treatment|June 8, 2015
Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patientsLisette Binkhorst, Jacqueline S L Kloth, Annelieke S de Wit, et al.
Pageof 3